Salute e Benessere

Global Health Exhibition to Showcase Unique Advances in AI-Enabled Diagnostics…

"We are in a transformative era in radiology, where artificial intelligence and now Gen AI is redefining the entire patient experience, from enhancing diagnostic accuracy to improving safety. This paradigm shift in healthcare allows for personalised and more precise treatment options," said Global Health Exhibition panellist Dr. Maha Gmira, Chief Technology Officer of SolutionAI. "We are in a transformative era in radiology, where artificial intelligence and now Gen AI is…
PR Newswire
26/09/2024

SciBase expands to new market in Pennsylvania and receives first order from…

"We are thrilled to commence a partnership with Seraly Dermatology Their focus on individual patient care is one of many reasons we are proud to partner with them. I'm also pleased to see that our recent U.S. team expansion is already having a positive impact on the U.S. market by increasing access of the Nevisense test to more patients in new geographic areas", says Pia Renaudin, CEO of SciBase. " We are thrilled to commence a partnership with Seraly Dermatology Their focus on…
PR Newswire
26/09/2024

Study Finds Lycomato® Improves Mitochondrial Function and Delays Cellular Aging

To assess the effectiveness of Lycomato in delaying cellular aging, researchers treated cells with rotenone, a compound that triggers mitochondrial dysfunction. Results showed that when cells were also pre-treated with Lycomato, mitochondrial function improved, mitochondrial ROS levels were reduced by about 70%, ATP levels restored to around 70% and the number of senescent cells was dramatically reduced to near-normal levels. Together, results suggest Lycomato and similar phytonutrient-rich…
PR Newswire
26/09/2024

Sultan bin Ahmed launches Small Hearts and Eyes Campaign at the National…

Sultan bin Ahmedlistened to a detailed explanation from Dr.Ahmed Mohammed Al Kamali, a pediatric heart surgery specialist, about the cases that have undergone surgery, as well as those that will be examined and diagnosed to determine the appropriate type of treatment, whether through catheterization or heart surgery for the sick children. The Chairman of the Sharjah Media Council, learned about the procedures followed in diagnosing medical cases and determining the treatment...
PR Newswire
26/09/2024

Evaxion significantly expands vaccine development collaboration with MSD

Agreement provides MSD with options to license Evaxion's preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3Evaxion will host a conference call and webcast to discuss the agreement on September 27, 2024COPENHAGEN, Denmark, Sept.26, 2024(GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it has entered into an option and license agreement with...
Nasdaq GlobeNewswire
26/09/2024

Johns Hopkins Aramco Healthcare (JHAH) Partners with TruDoc Healthcare to…

Commenting on the initiative Dr. Michael Walsh, CEO, JHAH said, "This initiative represents a pivotal moment in our mission at JHAH to innovate and personalize healthcare. Our expanded telehealth services, launched in 2023, now offers round-the-clock primary care, eliminating barriers such as travel and wait times, and seamlessly integrating into our patients' lives. With this latest advancement, we are enabling patients to transition from hospital to home while maintaining continuous…
PR Newswire
26/09/2024

Orion's collaboration partner Bayer submits application to U.S. FDA for third…

ORION CORPORATIONINVESTOR NEWS26 SEPTEMBER 2024 at 11.00 EEST Orion's collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster Orion's collaboration partner Bayer today announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for the oral androgen receptor inhibitor (ARi) darolutamide. Bayer is seeking approval for...
Nasdaq GlobeNewswire
26/09/2024

AB Science provides an update on the microtubule program AB8939 and in…

PRESS RELEASEAB SCIENCE PROVIDES AN UPDATE ON THE MICROTUBULE PROGRAM AB8939 AND IN PARTICULAR THE ABILITY OF AB8939 TO GENERATE RESPONSE ON MECOM REARRANGEMENTParis, 26 September 2024, 8.30am CETAB Science SA(Euronext - FR0010557264 - AB) today provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement.AB8939 is a novel microtubule destabilizer currently evaluated in phase 1 clinical trial (study...
Nasdaq GlobeNewswire
26/09/2024

Press Release: Availability of the Q3 2024 Aide mémoire

Availability of the Q3 2024 Aide mémoireParis, France – September 26, 2024. Sanofi announced today that its Q3 2024 Aide mémoire is available on the "Investors" page of the company's website:Third quarter 2024 results (sanofi.com)As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and...
Nasdaq GlobeNewswire
26/09/2024

Crossject announces its eligibility for France's PEA-PME investment scheme

Enables French retail investors to buy securities under preferential tax conditions Dijon, France Sept 26, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO®,today confirms its eligibility for PEA-PME, a French government investment scheme which enables retail investors to acquire a portfolio of European securities whilst benefiting from...
Nasdaq GlobeNewswire
26/09/2024

Positive phase III results for Roche's Gazyva/Gazyvaro show superiority to…

Positive phase III results for Roche's Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis The REGENCY study met its primary endpoint, demonstrating statistically significant and clinically meaningful treatment benefits in people with active lupus nephritisGazyva/Gazyvaro is designed to target an underlying cause of lupus nephritis, aiming to prevent or delay progression to end-stage kidney disease 1,2 Lupus nephritis is a potentially...
Nasdaq GlobeNewswire
26/09/2024

PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune…

Over a decade of clinical data, experience and know-how with lead polyclonal Treg cell therapy PTG-007 in type-1 diabetes will accelerate CAR-Treg candidate developmentNew CAR-Treg cell therapy candidate is most advanced in growing engineered pipelineTwo new patents granted for engineered cell therapies, in U.S. and Japan Gdańsk, Poland – 26 September 2024– PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cellular therapies for a...
Nasdaq GlobeNewswire
26/09/2024

Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)

For media and investors only Indicated for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the Netherlands, September 26, 2024:Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Joenja® (leniolisib) for the treatment of...
Nasdaq GlobeNewswire
26/09/2024

ISUOG 2024 | Redefining Women's Health with SonoScape's New Fenix 80 Series

With its continued commitment to innovation and excellence, SonoScape remains at the forefront of advancing women's health through cutting-edge technology. The successful launch of the Fenix 80 Series at ISUOG 2024 underscores the company's dedication to empowering healthcare professionals with the tools they need to deliver better outcomes for patients worldwide. As SonoScape looks ahead, it is poised to further shape the future of medical imaging and provide transformative solutions that…
PR Newswire
26/09/2024

Personalised Energy Expenditure Data Enhances Weight Loss in Obesity: New Study…

Study Design: The assessor-blinded, randomised controlled trial involved 52 participants with class 3 obesity (BMI µ 42 Kg/m2), divided into an intervention group receiving personalised energy expenditure data and a standard care group. Over 24 weeks, the intervention group achieved greater weight loss and improved metabolic outcomes. Study Design : The assessor-blinded, randomised controlled trial involved 52 participants with class 3 obesity (BMI µ 42 Kg/m 2 ), divided into an intervention...
PR Newswire
26/09/2024

Global Prostate Cancer Diagnostics Market to Observe Stunning Growth at a CAGR…

Key Takeaways from the Prostate Cancer Diagnostics Market Report Key Takeaways from the Prostate Cancer Diagnostics Market Report To read more about the latest highlights related to the prostate cancer diagnostics market, get a snapshot of the key highlights entailed in the Global Prostate Cancer Diagnostics Market Report Prostate Cancer Diagnostics Overview Prostate cancer diagnostics involve a combination of tests and procedures aimed at detecting the presence of cancerous...
PR Newswire
25/09/2024

CDK 7 Inhibitors Market is Expected to Showcase a Significant Growth by 2034 |…

Key Takeaways from the CDK 7 Inhibitors Market Report Key Takeaways from the CDK 7 Inhibitors Market Report Discover which therapies are expected to grab the CDK 7 inhibitors market share @ CDK 7 Inhibitors Market Report CDK 7 Inhibitors Market Dynamics The CDK7 inhibitors market has gained significant attention in recent years, driven by thegrowing need for targeted cancer therapies. The market dynamics for CDK7 inhibitors are influenced by several factors, including...
PR Newswire
25/09/2024

Inventiva provides a corporate update and reports its unaudited 2024 first-half…

Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical powering of the study expected to be superior to 95% for both dosesevaluated in the trial.Baseline characteristics of patients randomized in the main cohort of NATiV3 remain consistent with the characteristics of patients enrolled in the completed Phase IIb, NATIVE, clinical trial.Blinded analyses of patients in NATiV3 suggest a positive...
Nasdaq GlobeNewswire
25/09/2024

SLEEVER® and CARBIOS globally launch world's first Home Compost biodegradable…

The SEELCAP® ONEGO innovation is the fruit of a long-term partnership between SLEEVER® and CARBIOS that combines their expertise to produce more environmentally friendly packaging securitySEELCAP® ONEGO will be presented on the SLEEVER (RF14, Hall Ravel) and CARBIOS (VA17, Hall Verrière) stands at LuxePack Monaco, to be held from 30 September to 2 October 2024 at the Grimaldi Forum Morangis and Clermont-Ferrand (France), Wednesday 25 September 2024 (18h00 CEST) :SLEEVER®, a French...
Nasdaq GlobeNewswire
25/09/2024

GUERBET : H1 2024 results.

H1 2024 results Very dynamic business activityH1 revenue: €419.2m, up 11.8% at CER 1 A trajectory driven by all activities and geographical areasSolid increase in profitabilityThe restated EBITDA margin 2was 15.4%, compared to 12.7% a year earlierOperating income almost tripled to €30.3mUpward revision of annual guidanceRevenue: expected growth of over 9% like-for-like and at CER (>8% previously)Profitability: restated EBITDA margin rate...
Nasdaq GlobeNewswire
25/09/2024

PHAXIAM Provides Business and Financial Update For the First Half of 2024

Continuous commitment to create a global leader in phage therapies to treat severe and resistant bacterial infections Ambitious development strategy on track with clear objectives set for the Prosthetic Joint Infections (PJI) strategic program Clinical readout expected before end of year 2024, including Updated Compassionate real life clinical data and PhagoDAIR pilot studyImminent Filing of Investigational New Drug Application (IND) in US and Clinical Trial Application (CTA) in...
Nasdaq GlobeNewswire
25/09/2024

UNION therapeutics announce results from the ADESOS Phase 2b study in atopic…

Mean percentage changes in EASI (Eczema Area and Severity Index) at Week 16 were: -55.1%, -52.2%, -61.4%, and -50.4%, in orismilast 20, 30, 40mg and placebo groups, respectively (p>0.05). Mean EASI at baseline was 23, the least severe reported in a Phase 2b/3 study in moderate to severe AD to date. This likely drove the high EASI placebo response also seen in other recent studies with more moderate patients. In the subgroup of patients with severe disease at baseline (EASI >21), active…
PR Newswire
25/09/2024

Boehringer Ingelheim expands cancer research at its Vienna site

Inauguration of Angelika Amon research building in Vienna Sustainable research building at a cost of EUR 60 million offers modern office and laboratory spaceOver the past five years, Boehringer's capital investments reached EUR 6.0 billionBoehringer Ingelheim is one of the world's leading research-oriented pharmaceutical companies. The clinical pipeline is constantly being further developed, and Boehringer Ingelheim expects new approvals also in oncology in the coming years.An...
Nasdaq GlobeNewswire
25/09/2024

Water Repellant for Textile Market Size to Grow USD 1153.4 Million by 2030 at a…

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-8L14536/Global_Water_Repellant_for_Textile_Market Get Free Sample : https://reports.valuates.com/request/sample/QYRE-Auto-8L14536/Global_Water_Repellant_for_Textile_Market Major Trends: The Water Repellent for Textile Market has seen significant growth due to the rising demand for durable and high-performance textiles across various industries such as apparel, outdoor gear, and home furnishings. The market is...
PR Newswire
25/09/2024
Altri  Comunicati